Press releases
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
-Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection after antibiotic treatment Saint-Prex, Switzerland and Parsippany, NJ, USA – August 9, 2022 – Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of […]
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
-New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body of evidence of the RBX2660 clinical development program – the largest, most robust program conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI). Saint-Prex, Switzerland […]
-
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022
-Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI) after antibiotic treatment, as part of Digestive Disease Week (DDW 2022). The congress will take place in San Diego, CA, and virtually from May 21 – 24, 2022. […]